clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-321Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSФармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностьюБелоусовЮ. Б.
д.м.н., проф., зав. кафедрой клинической фармакологии
clinvest@mail.ruhttps://orcid.org/0000-0002-2164-8290БелоусовД. Ю.
генеральный директор
SPIN-код: 6067-9067
clinvest@mail.ruГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», МоскваRussian FederationООО "Центр фармакоэкономических исследований", г. МоскваRussian Federation20062706201801321Copyright © Белоусов Ю.Б., Белоусов Д.Ю., 20182018Белоусов Ю.Б., Белоусов Д.Ю.Белоусов Ю.Б., Белоусов Д.Ю.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/321фармакоэкономикалевосименданхроническая сердечная недостаточностьReferencesStanton A. Therapeutic potential of rennin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389-94.Stanton A. Therapeutic potential of rennin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389-94.Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human rennin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005 Sep; 46: 569-76.Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human rennin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005 Sep; 46: 569-76.Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 Dec; 15: 3126-33.Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 Dec; 15: 3126-33.Pitt B., Remme W., Zannad F. et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and survival study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321.Pitt B., Remme W., Zannad F. et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and survival study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321.Lee C.R., Watkins M.L., Patterson J.H. et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.Lee C.R., Watkins M.L., Patterson J.H. et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.Hauptman P.J., Zimmer C., Udelson J. et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 2005 Nov; 46: 609-14.Hauptman P.J., Zimmer C., Udelson J. et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 2005 Nov; 46: 609-14.Spieker L.E., Mitrovic V., Noll G. et al. Acute hemodynamic and neurohumoral effects of selective ETa receptor blockade in patients with congestive heart failure: ET 003 Investigators. J Am Coll Cardiol 2000; 35: 1745-52.Spieker L.E., Mitrovic V., Noll G. et al. Acute hemodynamic and neurohumoral effects of selective ETa receptor blockade in patients with congestive heart failure: ET 003 Investigators. J Am Coll Cardiol 2000; 35: 1745-52.Cheng J.W. Bosentan. Heart Dis 2003; 5: 161-9.Cheng J.W. Bosentan. Heart Dis 2003; 5: 161-9.Ono K., Matsumori A. Endothelin antagonism with bosentan: current status and future perspectives. Cardiovascular Drug Review 2002; 20: 1-18.Ono K., Matsumori A. Endothelin antagonism with bosentan: current status and future perspectives. Cardiovascular Drug Review 2002; 20: 1-18.Levin E.R., Kalman J., Samson W.K. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.Levin E.R., Kalman J., Samson W.K. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovascular Drug Review 2002; 20: 27-36.Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovascular Drug Review 2002; 20: 27-36.Rouleau J.L., Pfeffer M.A., Stewart D.J. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000; 356:1774.Rouleau J.L., Pfeffer M.A., Stewart D.J. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000; 356:1774.Packer M., Califf R.M., Constam M.A. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-6.Packer M., Califf R.M., Constam M.A. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-6.Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):68G-73G.Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):68G-73G.Haikala H., Nissinen E.,Etemadzadeh E. et all. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaction. J Cardiovasc PharmacolHaikala H., Nissinen E.,Etemadzadeh E. et all. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaction. J Cardiovasc PharmacolUkkonen H., Saraste M., Akkila J. et al. Miocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology and Terapeutics 2000; 68: 522-531.Ukkonen H., Saraste M., Akkila J. et al. Miocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology and Terapeutics 2000; 68: 522-531.Kaheinen P., Polessello P., Levijoki J., Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium cannels. J Cardiovasc Pharmacol 2001; 37: 367-374.Kaheinen P., Polessello P., Levijoki J., Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium cannels. J Cardiovasc Pharmacol 2001; 37: 367-374.Alvarez J., Taboada M., Rodriguez J. et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim 2005 Aug-Sep;52(7):389-94.Alvarez J., Taboada M., Rodriguez J. et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim 2005 Aug-Sep;52(7):389-94.Maytin M., Colucci W.S. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):26G-31G.Maytin M., Colucci W.S. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):26G-31G.Papp Z., Csapo K., Pollesello P. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005 Spring; 23 (1):71-98.Papp Z., Csapo K., Pollesello P. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005 Spring; 23 (1):71-98.Parissis J.T., Panou F., Farmakis D. et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005 Aug 1;96(3):423-6.Parissis J.T., Panou F., Farmakis D. et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005 Aug 1;96(3):423-6.Avgeropoulou C., Andreadou I., Markantonis-Kyroudis S. et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005 Aug;7(5):882-7.Avgeropoulou C., Andreadou I., Markantonis-Kyroudis S. et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005 Aug;7(5):882-7.Paraskevaidis I.A., Parissis J.T., Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005 Jul; 3(3): 243-7.Paraskevaidis I.A., Parissis J.T., Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005 Jul; 3(3): 243-7.Kivikko M., Antila S., Eha J. et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin. Pharmacol 2002; 42:43-51.Kivikko M., Antila S., Eha J. et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin. Pharmacol 2002; 42:43-51.Kivikko M., Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005;11(4):435-55.Kivikko M., Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005;11(4):435-55.Poder P., Eha J., Sundberg S. еt al. Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study. J Clin Pharmacol October 1, 2004; 44(10): 1143 - 1150.Poder P., Eha J., Sundberg S. еt al. Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study. J Clin Pharmacol October 1, 2004; 44(10): 1143 - 1150.Poder P., Eha J., Antila S. еt al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003 Sep-Nov; 17(5-6):451-8.Poder P., Eha J., Antila S. еt al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003 Sep-Nov; 17(5-6):451-8.Antila S., Eha J., Heinpalu M. еt al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol. 1996; 49(6): 451-8.Antila S., Eha J., Heinpalu M. еt al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol. 1996; 49(6): 451-8.Moiseyev V.S. et al. Safety and efficacy of a novel calcium sencitezer, Levosimendan, in patients with LVF due to an acute myocardial infarction. RUSSLAN. Eur Heart J 2002; 23: 1422-32.Moiseyev V.S. et al. Safety and efficacy of a novel calcium sencitezer, Levosimendan, in patients with LVF due to an acute myocardial infarction. RUSSLAN. Eur Heart J 2002; 23: 1422-32.Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003 May;4 Suppl 2:34S-38S.Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003 May;4 Suppl 2:34S-38S.Cleland J.G., Takala A., Apajasalo еt al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003 Jan;5(1):101-8.Cleland J.G., Takala A., Apajasalo еt al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003 Jan;5(1):101-8.Cleland J.G., Ghosh J., Freemantle N. еt al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004 Jun;6(4):501-8.Cleland J.G., Ghosh J., Freemantle N. еt al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004 Jun;6(4):501-8.Mebazaa A., Barraud D., Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005 Sep 19;96(6A):74G-79G.Mebazaa A., Barraud D., Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005 Sep 19;96(6A):74G-79G.Faivre V., Kaskos H., Callebert J. et al.Cardiac and Renal Effects of Levosimendan, Arginine Vasopressin, and Norepinephrine in Lipopolysaccharide-treated Rabbits.Anesthesiology 2005 Sep;103(3):514-521.Faivre V., Kaskos H., Callebert J. et al.Cardiac and Renal Effects of Levosimendan, Arginine Vasopressin, and Norepinephrine in Lipopolysaccharide-treated Rabbits.Anesthesiology 2005 Sep;103(3):514-521.Morelli A., De Castro S., Teboul J.L. et all. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005 May;31(5):638-44.Morelli A., De Castro S., Teboul J.L. et all. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005 May;31(5):638-44.Follath F., Franco F., Cardoso J.S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):80G-5G.Follath F., Franco F., Cardoso J.S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):80G-5G.Garcia-Gonzalez M.J., Dominguez-Rodriguez A., Ferrer-Hita J.J. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005 Jun;45(6):704-8.Garcia-Gonzalez M.J., Dominguez-Rodriguez A., Ferrer-Hita J.J. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005 Jun;45(6):704-8.Zobel C., Reuter H., Schwinger R.H. Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan. Med Klin (Munich) 2004 Dec 15;99(12):742-6.Zobel C., Reuter H., Schwinger R.H. Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan. Med Klin (Munich) 2004 Dec 15;99(12):742-6.Siirila-Waris K., Suojaranta-Ylinen R., Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005 Jun;19(3):345-9.Siirila-Waris K., Suojaranta-Ylinen R., Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005 Jun;19(3):345-9.Wang J., Weil M.H., Tang W. et al. Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade.J Lab Clin Med. 2005 Sep;146(3):179-83.Wang J., Weil M.H., Tang W. et al. Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade.J Lab Clin Med. 2005 Sep;146(3):179-83.Verre M., Bossio F., Durante M. et al. Use of levosimendan after cardiac arrest by ventricular fibrillation: a case report. Clin Ter 2005 May-Jun;156(3):111-4.Verre M., Bossio F., Durante M. et al. Use of levosimendan after cardiac arrest by ventricular fibrillation: a case report. Clin Ter 2005 May-Jun;156(3):111-4.Kasikcioglu H.A., Unal S., Tartan Z. et al. Effects of levosimendan on left ventricular functional remodeling and exercise intolerance: a tissue Doppler study. J Int Med Res 2005 Jul-Aug; 33(4):397-405.Kasikcioglu H.A., Unal S., Tartan Z. et al. Effects of levosimendan on left ventricular functional remodeling and exercise intolerance: a tissue Doppler study. J Int Med Res 2005 Jul-Aug; 33(4):397-405.Белоусов Ю.Б., Белоусов Д.Ю., Григорьев В.Ю., Бекетов А.С., Медников О.И. Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью // Сердечная недостаточность, №1 2006 г. стр. том 7, №1 (35), 2006, стр.32-38.Белоусов Ю.Б., Белоусов Д.Ю., Григорьев В.Ю., Бекетов А.С., Медников О.И. Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью // Сердечная недостаточность, №1 2006 г. стр. том 7, №1 (35), 2006, стр.32-38.Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized, doubleblind study. Lancet 2002;360(9328):196–202.Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized, doubleblind study. Lancet 2002;360(9328):196–202.WHO Commission on Macroeconomics and Health. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO, 2001WHO Commission on Macroeconomics and Health. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO, 2001Госкомстат РФ, 2001-2004 гг., www.gks.ruГоскомстат РФ, 2001-2004 гг., www.gks.ruWillens HJ, Chakko S, Simmons J, Kessler KM. Cost-effectiveness in clinical cardiology. Part 1: coronary artery disease and congestive heart failure. Chest 1996;109:1359 –69.Willens HJ, Chakko S, Simmons J, Kessler KM. Cost-effectiveness in clinical cardiology. Part 1: coronary artery disease and congestive heart failure. Chest 1996;109:1359 –69.Ардашев А.В., Желяков Е.Г. Применение имплантируемых кардиовертеров-дефибрилляторов для профилактики внезапной сердечной смерти //Российский кардиологический журнал, 2004 г., №3 стр.35-41Ардашев А.В., Желяков Е.Г. Применение имплантируемых кардиовертеров-дефибрилляторов для профилактики внезапной сердечной смерти //Российский кардиологический журнал, 2004 г., №3 стр.35-41Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998;19(Suppl P):P32 –P39.Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998;19(Suppl P):P32 –P39.Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890 –6.Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890 –6.Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. PharmacoEconomics 2001;19:901 – 16.Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. PharmacoEconomics 2001;19:901 – 16.Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001;110(Suppl 7A):74S–80S.Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001;110(Suppl 7A):74S–80S.Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytictherapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418 –24.Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytictherapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418 –24.Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred lifesaving interventions and their cost-effectiveness. Risk Anal 1995;15:369 –90.Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred lifesaving interventions and their cost-effectiveness. Risk Anal 1995;15:369 –90.Nainggolan L. CASINO results: should docs gamble on Levosimendan. www.theHeart.org.Nainggolan L. CASINO results: should docs gamble on Levosimendan. www.theHeart.org.Моисеев В.С., Poder P., Андреев Н.А., Руда М.Я., Голиков А.П., Лазебник Л.Б., Кобалава Ж.Д., Lehtonen L., Laine Т., Nieminen М., Lie К. от имени участников исследования RUSSLAN. Безопасность и эффективность Левосимендана у больных левожелудочковой недостаточностью при остром инфаркте миокарда. Рандомизированное двойное слепое плацебоконтролируемое исследование (RUSSLAN) // Клин. фармакол. тер., 2004, 13 (4), стр. 32-38.Моисеев В.С., Poder P., Андреев Н.А., Руда М.Я., Голиков А.П., Лазебник Л.Б., Кобалава Ж.Д., Lehtonen L., Laine Т., Nieminen М., Lie К. от имени участников исследования RUSSLAN. Безопасность и эффективность Левосимендана у больных левожелудочковой недостаточностью при остром инфаркте миокарда. Рандомизированное двойное слепое плацебоконтролируемое исследование (RUSSLAN) // Клин. фармакол. тер., 2004, 13 (4), стр. 32-38.The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001. 345(7): p. 494-502.The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001. 345(7): p. 494-502.The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000, 342: 145–153.The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000, 342: 145–153.The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357
The authors declare that there are no conflicts of interest present.